Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 26, 2017
Pharmacy Choice - Pharmaceutical News - Findings from Columbia University Medical Center Provides New Data on Head and Neck Cancer (Impact of PI3K/AKT/mTOR pathway activation on the... - March 26, 2017

Pharmacy News Article

 3/20/17 - Findings from Columbia University Medical Center Provides New Data on Head and Neck Cancer (Impact of PI3K/AKT/mTOR pathway activation on the...

Findings from Columbia University Medical Center Provides New Data on Head and Neck Cancer (Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas)

By a News Reporter-Staff News Editor at Clinical Oncology Week Investigators publish new report on Oncology - Head and Neck Cancer. According to news reporting originating from New York City, New York, by NewsRx correspondents, research stated, "The PI3K/AKT/mTOR signaling pathway has emerged as one of the most frequently deregulated in head and neck squamous cell carcinomas (HNSCC). Numerous alterations of various upstream and downstream components have been described; however, their prognostic significance and impact on HNSCC patient survival remains to be established."

Our news editors obtained a quote from the research from Columbia University Medical Center, "This was addressed using an unbiased cohort of 93 consecutive and homogeneous surgically treated HNSCC patients and results confirmed in 432 HNSCC patients. Our findings reveal the high prevalence of S6 phosphorylation, a surrogate marker of mTORC1 activation, in HNSCC specimens (>70%) and, more importantly, demonstrate its relevance on clinical outcome. Phosphorylation of ribosomal protein S6 on either Ser235/236 or Ser240/244 was consistently and significantly correlated with favorable prognosis, although with differences depending on the tumor site. Thus, p-S6 expression was significantly correlated with better disease-specific survival specifically in the subgroup of laryngeal carcinoma patients (p <0.001). In addition, multivariate regression models revealed p-S6 to be an inverse and independent predictor of lymph-node metastasis (p=0.004) and distant metastasis (p=0.006). Taken together, this study unveils an unprecedented correlation of mTOR activation with improved clinical outcome in patients with laryngeal carcinomas and uncovers the potential of p-S6 expression as a good prognostic biomarker and an inverse predictor of lymph node and distant metastases."

According to the news editors, the research concluded: "These results should be of broad interest as immunohistochemical detection of p-S6 may help to stratify patients and guide treatment decisions."

For more information on this research see: Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. Oncotarget, 2016;7(20):29780-93 (see also Oncology - Head and Neck Cancer).

The news editors report that additional information may be obtained by contacting D. Garcia-Carracedo, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, United States. Additional authors for this research include M.A. Villaronga, S. Alvarez-Teijeiro, F. Hermida-Prado, I. Santamaria, E. Allonca, L. Suarez-Fernandez, M.V. Gonzalez, M. Balbin, A. Astudillo, P. Martinez-Camblor, G.H. Su, J.P. Rodrigo and J.M Garcia-Pedrero.

Keywords for this news article include: Oncology, New York City, United States, Head and Neck Cancer, Squamous Cell Carcinoma, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Mar 27: HIV Medications: Newer Drugs, Newer Guidelines
Last Chance
Mar 28: Adverse Drug Events: Risk Reduction and Reporting
Mar 30: Know Your Value, Know Your Worth: Provider Status in Pharmacy
Mar 31: Medication Safety & Drug Safety Alerts
Apr 03: Headache Disorders: Focus on Migraines & Tension Headaches
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415